Evidence map›Paper›PMID 35585976›Full record

ArticleFrontiers in immunology2022

Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas.

Abdouramane Traoré, Merepen A Guindo, Drissa Konaté, Bourama Traoré, Seidina A Diakité, Salimata Kanté, Assitan Dembélé, Abdourhamane Cissé, Nathan C Incandela, Mamoudou Kodio and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 7 countries.

Abdouramane TraoréImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Merepen A GuindoImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Drissa KonatéImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Bourama TraoréDepartment of Ministry of Health and Social Development, Hopital de Dermatologie de Bamako (HDB), Bamako, Mali.
Seidina A DiakitéImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Salimata KantéImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Assitan DembéléImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Abdourhamane CisséImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Nathan C IncandelaCenter for Polymers and Organic Solids, Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, United States.
Mamoudou KodioDepartment of Ministry of Health and Social Development, Hopital de Dermatologie de Bamako (HDB), Bamako, Mali.
Yaya I CoulibalyDepartment of Ministry of Health and Social Development, Hopital de Dermatologie de Bamako (HDB), Bamako, Mali.
Ousmane FayeDepartment of Ministry of Health and Social Development, Hopital de Dermatologie de Bamako (HDB), Bamako, Mali.
Andrey V KajavaMontpellier Cell Biology Research Center (CRBM), University of Montpellier, CNRS, Montpellier, France.
Federico PratesiImmuno-Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Paola MiglioriniImmuno-Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Anna Maria PapiniInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Florence, Italy.
Lorenzo PaciniInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Florence, Italy.
Paolo RoveroInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmaceutical Sciences and Nutraceutics, University of Florence, Florence, Italy.
Fosca ErranteInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmaceutical Sciences and Nutraceutics, University of Florence, Florence, Italy.
Mahamadou DiakitéImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Myriam Arevalo-HerreraDepartment of Immunology, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Socrates HerreraDepartment of Immunology, Caucaseco Scientific Research Center, Cali, Colombia.
Giampietro CorradinBiochemistry Department , University of Lausanne, Lausanne, Switzerland.
Saidou BalamImmunogenetic Laboratory and Parasitology, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Université des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of Bamako · MLUniversity of Florence · ITCaucaseco Scientific Research Center · COUniversity of Pisa · ITUniversité de Montpellier · FRUniversity Hospital Regensburg · DEUniversity of California, Santa Barbara · USUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the global interest and the unprecedented number of scientific studies triggered by the COVID-19 pandemic, few data are available from developing and low-income countries. In these regions, communities live under the threat of various transmissible diseases aside from COVID-19, including malaria. This study aims to determine the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroreactivity of antibodies from COVID-19 and pre-COVID-19 samples of individuals in Mali (West Africa). Blood samples from COVID-19 patients (n = 266) at Bamako Dermatology Hospital (HDB) and pre-COVID-19 donors (n = 283) from a previous malaria survey conducted in Dangassa village were tested by ELISA to assess IgG antibodies specific to the full-length spike (S) protein, the receptor-binding domain (RBD), and the receptor-binding motif (RBM

Indexed as

COVID-19MalariaAntibodies, ViralHumansMaliPandemicsSARS-CoV-2Antibodies, ViralCOVID-19 samplescross-reactivitymalaria endemic-areaPre-COVID-19 samplesSARS-CoV-2 S proteinseroreactivity

Identifiers

PMID35585976
PMCPMC9109707
OpenAlexW4224943979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.